focus -WSS

focus

author：leisure time 2025-10-02 21:06:43 - browse：4329

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： The Readout: Lenmeldy, GLP

WSS

Man killed during FBI raid in connection with threats against Biden, other officials

Friends ask where James Watson's attitudes about race came from

Maui's cultural, historic landmarks damaged in the devastating wildfires

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Naloxone nonprofit donates 200,000 doses after FDA approval

Wegovy trial has doctors encouraged over new possibilities

explore

focus

focus

Affirmative action in medical school literally saved lives

Drastic changes should bring profitability, startup health insurers say

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Decaf coffee targeted by food safety group under obscure FDA rule

As demand for Covid shots wanes, Moderna seeks its next success

Man killed during FBI raid in connection with threats against Biden, other officials

Activists slam private health insurers over coverage restrictions

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Wildfire smoke exposes gaps in outdoor worker protections

Police still searching for prisoner who escaped from NYC hospital

focus

Abortion pill Supreme Court ruling could impact entire drug industry

Merck drug for rare lung condition set for approval in U.S.

Washington mulls new rules to avert another Change Healthcare

The best solution to the drug shortages problem

Maui's cultural, historic landmarks damaged in the devastating wildfires

Patient advocates debate FDA's accelerated approval process

hotspot

explore

focus

focus